I don't use AI often, but:
Northwest Biotherapeutics (NWBO) may have added these references to their patent to strengthen its claims and demonstrate scientific support for their approach. By including studies on CTLA-4 blockade and dendritic cell vaccines, they align their application with established research, showing a foundation for efficacy in combining therapies.
Theoretically, this addition could position NWBO for potential partnerships with companies developing CTLA-4 inhibitors, like Bristol-Myers Squibb, AstraZeneca, or BioNTech, as their technologies could complement each other. Partnerships often enhance development and market access for such combinations.
Market Data 
Markets 
